LY3437943 Is Retatrutide, and You Can Buy It for Research at Peptara Labs
LY3437943 is retatrutide: it is Eli Lilly's lab code for the same compound. We counted both names in the trial registry, and 26 of 33 study titles use the code, against 18 that use the name.
Links to Peptara Labs are affiliate links, and we may earn a commission when you buy through them.
Buy LY3437943 (Retatrutide) at Peptara Labs
How often each name is used
We read the titles of all 33 retatrutide studies on ClinicalTrials.gov on September 24, 2026.
| Title uses | Studies |
|---|---|
| LY3437943 | 26 |
| Retatrutide | 18 |
| Both names | 12 |
| Only LY3437943 | 14 |
So if you only search for "retatrutide", you miss 14 studies that use the code alone.
One molecule, five names
| Name | What it is |
|---|---|
| LY3437943 | Eli Lilly's lab code |
| Retatrutide | The official drug name |
| Reta | Short name used online |
| GLP-3 | A nickname. There is no GLP-3 receptor |
| Triple agonist | A description: it acts on GLP-1, GIP and glucagon receptors |
How Eli Lilly's codes work
Eli Lilly gives compounds a code that starts with LY while they are in research. The same registry shows tirzepatide as LY3298176, the code it had before it became Mounjaro. Retatrutide's code, LY3437943, appeared in the 2022 paper that first described it.
LY3437943 timeline
| When | What happened |
|---|---|
| March 2019 | First registered study starts |
| 2022 | Discovery paper published (Coskun et al., Cell Metabolism) |
| 2023 | Phase 2 results published (Jastreboff et al., NEJM) |
| 2023 to 2030 | 14 phase 3 trials, 5 finished so far |
| 2026 | Still not FDA approved |
For every trial, see retatrutide clinical trials.
Where the code shows up
The code even appears on Peptara Labs' batch certificate, which names the sample "Retatrutide (LY3437943)". A certificate shows what one lot tested as; it does not show a product is safe or approved for use in people.
Every number on that certificate is explained on retatrutide lab test results.
Search tips
- Search both LY3437943 and retatrutide.
- Treat GLP-3 and reta as the same compound.
- Check that a seller's certificate names retatrutide or LY3437943, and gives a measured mass near 4731 Da.
- Use how to check retatrutide quality to read any certificate.
Where to buy LY3437943 for research
Peptara Labs sells it as retatrutide: $205 for a 20mg vial, or $123 each for 10, with free shipping and a 60-day money-back guarantee. See the best place to buy retatrutide online.
Frequently asked questions
What is LY3437943?
Eli Lilly's lab code for retatrutide.
Is LY3437943 the same as retatrutide?
Yes. Both names refer to the same molecule.
Why do trial listings use the code?
The code came first. 14 of the 33 registered studies use only LY3437943 in their title.
What is GLP-3?
A nickname for retatrutide. There is no GLP-3 receptor.
What does reta mean?
A short name people use online for retatrutide.
Who made LY3437943?
Eli Lilly and Company.
When did research on LY3437943 start?
The first registered study started in March 2019. The discovery paper came out in 2022.
Is LY3437943 FDA approved?
No. See is retatrutide FDA approved.
What was tirzepatide's code?
LY3298176.
Where can I buy LY3437943?
Peptara Labs sells it under the name retatrutide, for research use only.
How much does it cost?
$205 per 20mg vial at Peptara Labs, or $123 per vial when you buy 10.
Buy LY3437943 (Retatrutide) at Peptara Labs
Sources
- ClinicalTrials.gov search for retatrutide, read September 24, 2026
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab 2022 (PMID 35985340)
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023 (PMID 37366315)
- Titreon Analytical certificate COA-2026-6928, lot RETA-260512-A (4 pages)
- Peptara Labs retatrutide page, read September 24, 2026